tiprankstipranks
Neurogene announces first patient dosed in high-dose cohort of NGN-401
PremiumThe FlyNeurogene announces first patient dosed in high-dose cohort of NGN-401
1M ago
Neurogene initiated with an Outperform at Baird
PremiumThe Fly
Neurogene initiated with an Outperform at Baird
1M ago
Neurogene’s NGN-401 Therapy Advances under FDA START Program
PremiumCompany Announcements
Neurogene’s NGN-401 Therapy Advances under FDA START Program
2M ago
Neurogene reports Q1 EPS ($1.00), consensus ($1.13)
PremiumThe FlyNeurogene reports Q1 EPS ($1.00), consensus ($1.13)
2M ago
Neurogene Reveals Encouraging Gene Therapy Trial Results
PremiumCompany Announcements
Neurogene Reveals Encouraging Gene Therapy Trial Results
2M ago
Neurogene reports data from Phase 1/2 gene therapy clinical trial for NGN-401
PremiumThe Fly
Neurogene reports data from Phase 1/2 gene therapy clinical trial for NGN-401
2M ago
Neurogene Reports Positive Results in Rett Syndrome Trial
PremiumCompany AnnouncementsNeurogene Reports Positive Results in Rett Syndrome Trial
3M ago
Neurogene Enhances Executive Compensation and Severance Terms
PremiumCompany Announcements
Neurogene Enhances Executive Compensation and Severance Terms
4M ago
Neurogene Inc. Files Key SEC Report
PremiumCompany Announcements
Neurogene Inc. Files Key SEC Report
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100